What it sells
AI longevity-science company building a Longevity Foundation Model from cross-species, single-cell data to find anti-aging drug targets, with a wet-dry-wet validation loop.
Business model breakdown
Buyer: who owns the budget?
UnverifiedBusiness development leads at pharma or consumers buying health tests.
Workflow: what inputs become what output?
Discover conserved aging signals across species, model gene combinations, validate in wet lab, feed back to relearn.
Economics: what it saves and how it charges
Precision health (methylation-based biological age, genetic risk testing) is described as the early commercial entry, alongside a drug-discovery pipeline.
Distribution: how it reaches customers
Open partnership inquiries; precision health testing as early commercial entry.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-17 | Seed+ | nearly CNY 100M | — | news.pedaily.cn |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.